Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP

Journal of Clinical Investigation

Volumn 106, Issue 1, 2000, Pages 107-116

  Kaufmann, Jocelyne E ^a   Oksche, Alexander ^b   Wollheim, Claes B ^a   Günther, Gabriele ^b   Rosenthal, Walter ^b   Vischer, Ulrich M ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; VASOPRESSIN; VASOPRESSIN V2 RECEPTOR; VON WILLEBRAND FACTOR;

ARTICLE; HEMOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VON WILLEBRAND DISEASE;

EID: 0033946470     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9516     Document Type: Article

References (44)

1. Vischer, U.M., and de Moerloose, P. 1999. von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease. Crit. Rev. Oncol. Hematol. 30:93-109.
2. Sadler, J.E. 1998. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67:395-424.
3. Nichols, T.C., et al. 1995. Function of von Willebrand factor after crossed bone marrow transplantion between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc. Natl. Acad. Sci. USA. 92:2455-2459.
4. Wagner, D.D., Olmsted, J.B., and Marder, V.J. 1982. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J. Cell Biol. 95:355-360.
5. Mannucci, P.M., Raggeri, Z.M., Pareti, F.I., and Capitanio, A. 1977. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1:869-872.
6. Mannucci, P.M. 1997. Desmopressin (DDAVP) in the treatment of bleeding disorders the first 20 years. Blood. 90:2515-2521.
7. Birnbaumer, M., et al. 1992. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 357:333-335.
8. Lolait, S.J., et al. 1992. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipdus. Nature. 357:336-339.
9. Bichet, D.G., et al. 1998. Hemodynamic and coagulation responses to 1-desamino|8-D-arginine| vasopressin in patients with congenital nephrogenic diabetes insipidus. N. Engl. J. Med. 318:881-887.
10. Bichet, D.G., et al. 1989. Epinephrine and DDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMPV2 receptor defective mechanism. Kidney. 36:859-866.
11. Kobrinsky, N.L., et al. 1985. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus. Lancet. 1:1293-1294.
12. Mannucci, P.M., Aberg, M., Nilsson, I.M. and Robertson, B. 1975. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br. J. Haematol. 30:81-93.
13. Vischer, U.M., and Wollheim, C.B. 1997. Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb. Haemost. 77:1182-1188.
14. Booth, F., Allington, M.J., and Cederholm-Williams, S.A. 1987. An in vitro model for the study of acute release of von Willebrand factor from: human endothelial cells. Br. J. Haematol. 67:71-78.
15. Moffat, E.H., Giddings, J.C., and Bloom, A.L. 1984. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br. J Haematol. 57:651-662.
16. Hashemi, S., Palmer, D.S., Aye, M.T., and Ganz, P.R. 1993. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J. Cell. Physiol. 154:496-505.
17. Loesberg, C., et al. 1998. The effect of calcium on the secretion of factor VIII-related antigen by cultured human endothelial cells. Biochem. Biophys. Acta. 763:160-168.
18. + associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J. Clin. Invest. 79:600-608.
19. Birch, K.A., Pober, J.S., Zavoico, G.B., Means, A.R., and Ewenstein, B.M. 1992. Calcium calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells. J. Cell Biol. 118:1501-1510.
20. + and cyclic adenosine monophosphate-dependent signaling in endothelia exocytosis. Blood. 91:118-127.
21. Vischer, U.M., Lang, U., and Wollheim, C.B. 1998. Autocrine regulation of endothelial exocytosis: von Willebrand factor release is induced by prostacyclin in cultured endothelial cells. FEBS Lett. 424:211-215.
22. Hegeman, R.J., van den Eijnden-Schrauwen, Y., and Emeis, J.J. 1998. Adenosine 3′:5′-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells. Thromb. Haemost. 79:853-858.
23. Oksche, A., and Rosenthal, W. 1998. The molecular basis of nephrogenic diabetes insipidus. J. Mol. Med. 76:326-337.
24. Gjertsen, B.T., et al. 1995. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action. J. Biol. Chem. 270:20599-20607.
25. Serradeil-Le Gal, C., et al. 1996. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. 98:2729-2738.
26. Vischer, U.M., Jornot, L., Wollheim, C.B., and Theler, J.M. 1995. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood. 85:3164-3172.
27. Oksche, A., Dehe, M., Schulein, R., Wiesner, B., and Rosenthal, W. 1998. Folding and cell surface expression of the vasopressin V2 receptor: requirement of the intracellular C-terminus. FEBS Lett. 424:57-62.
28. Fay, M.J., Du, J., Yu, X., and North, W.G. 1996. Evidence for expression of vasopressin V2 receptor mRNA in human lung. Peptides. 17:477-481.
29. Herrera, P.L., et al. 1991. Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene. Development. 113:1257-1265.
30. Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. 9.31-9.57.
31. Ruggeri, Z.M., Mannucci, P.M., Lombardi, R., Federici, A.B., and Zimmerman, T.S. 1982. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 59:1272-1278.
32. Vischer, U.M., et al. 1997 Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb. Haemost. 77:387-393.
33. Borchiellini, A., et al. 1996. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 88:2951-2958.
34. Rickles, F.R., Hoyer, L.W., Rick, M.E., and Ahr, D.J. 1976. The effects of epinephrine infusion in patients with von Willebrand's disease. J. Clin. Invest. 57:1618-1625.
35. Cohen, R.J., Epstein, S.E., Cohen, L.S., and Dennis, L.H. 1968. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation. Lancet. 2:1264-1266.
36. Vischer, U.M., Barth, U., and Wollheim, C.B. 2000. Regulated von Willebrand factor (vWF) secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:883-891.
37. Rhodes, C.J., and Halban, P.A. 1987. Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway. J. Cell Biol. 105:145-153.
38. Bernat, A., et al. 1997. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Ther. 282:597-602.
39. Gader, A.M., da Costa, J., and Cash, J.D. 1973. A new vasopressin analogue and fibrinolysis. Lancet. 2:1417-1438.
40. Nilsson, I.M., Vilhardt, H., Holmberg, L., and Astedt, B. 1982. Association between factor VIII related antigen and plasminogen activator. Acta Med. Scand. 211:105-112.
41. Rosnoblet, C., et al. 1999. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19:1796-1803.
42. Datta, Y.H., Youssoufian, H., Marks, P.W., and Ewenstein, B.M. 1999. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells. Blood. 94:2696-2703.
43. Emeis, J.J., et al. 1997. An endothelial storage granule for tissue-type plasminogen activator. J. Cell Biol. 139:245-256.
44. Rosenberg, J. B., et al. 1998. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J. Clin. Invest. 101:613-624.